𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors

✍ Scribed by Mariana Verdelho Machado; António Gouveia Oliveira; Helena Cortez-Pinto


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
262 KB
Volume
52
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Hepatic steatosis (HS) is frequent in patients with hepatitis C virus (HCV) infection, occurring in 40%-80%, associating with metabolic and virus-related factors, namely, genotype 3 and viral load. Human immunodeficiency virus (HIV) infection and antiretroviral treatment seem to be risk factors for HS. Several studies addressed this issue in coinfected patients, with discrepant results. A meta-analysis was performed on the HS risk factors in coinfected patients. Eligible studies were identified through structured keywords including coinfection, HCV, HIV, and steatosis in relevant databases including PubMed. Pooled odds ratios (ORs) and confidence limits (CIs) were obtained with the random-effects model and the DerSimonian-Laird method. Twelve studies, including 1,989 coinfected patients, were selected. Twenty percent were infected with HCV genotype 3. The overall prevalence of HS was 50.8% (23%-72%). Four studies also included 1,540 HCV monoinfected patients, not showing an increased risk for HS in coinfected patients (OR 1.61, 95% CI 0.84-3.10, P = 0.151). In coinfected patients, HS was associated with higher body mass index (OR 1.13, 95% CI 1.07-1.19, P < 0.001), diabetes mellitus (OR 2.32, 95% CI 1.32-4.07, P = 0.003), elevated alanine aminotransferase levels (OR 1.28, 95% CI 1.02-1.61, P = 0.035), necroinflammatory activity (OR 1.72, 95% CI 1.11-2.67, P = 0.016), and fibrosis (OR 1.67, 95% CI 1.20-2.34, P = 0.003). No associations were found between HS and gender, other metabolic factors (dyslipidemia, glucose, metabolic syndrome), HCV-related factors (genotype, viral load), or HIV-related factors (viral load, CD4 count, antiretroviral therapy, and class of medication).

Conclusion:

In coinfected patients, hs does not seem to be more frequent than in hcv monoinfected patients and is mostly associated with metabolic factors, such as increased weight, diabetes mellitus, and more severe liver disease. the fact that no associations with hcv factors were found may be due to the small percentage of genotype 3-infected patients.


📜 SIMILAR VOLUMES


Steatohepatitis: Risk factors and impact
✍ Richard K. Sterling; Melissa J. Contos; Paula G. Smith; R. Todd Stravitz; Velimi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

Hepatic steatosis has been reported in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection. However, the features of steatohepatitis, including cytologic ballooning and pericellular fibrosis, its risk factors, and the impact on disease severity in such patients are unknown. To ass

Survival and recurrence of hepatitis C a
✍ Jean-Charles Duclos-Vallée; Cyrille Féray; Mylène Sebagh; Elina Teicher; Anne-Ma 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 1 views

Liver transplantation in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is a recent indication. In a single center, we have compared the survival and severity of recurrent HCV infection after liver transplantation in HIV-HCV-coinfected and HCV-monoinfected pa

Fast fibrosis progression between repeat
✍ Juan Macías; Juan Berenguer; Miguel A. Japón; José A. Girón; Antonio Rivero; Lui 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 1 views

A few studies have assessed the observed fibrosis progression between serial liver biopsies (LB) in human immunodeficiency virus (HIV) / hepatitis C virus (HCV)-coinfected patients. Approximately half of the patients progressed at least one fibrosis stage over a short period of time. The risk factor

Hepatic steatosis is a risk factor for h
✍ Kazuyuki Ohata; Keisuke Hamasaki; Kan Toriyama; Kojiro Matsumoto; Akira Saeki; K 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 3 views

## Abstract ## BACKGROUND Hepatic steatosis is one of the histopathologic features of chronic hepatitis C. It was reported recently that the expression of hepatitis C virus (HCV) core protein in transgenic mice induced hepatocellular carcinoma (HCC) in association with steatosis. The objective of